Eli Lilly and Company
Pharmaceutical & Health Products · Lobbying Client
Eli Lilly and Company's Federal Lobbying Record
At $22.3M in disclosed federal lobbying, Eli Lilly and Company ranks as a major spender — well above the typical filer. Outlays in this range generally reflect a sustained presence in Washington, with at least one full-time government affairs lead and a stable of outside lobbyists engaged on the organization's priority issues.
Across the 5-year window from 2020 to 2024, Eli Lilly and Company's annual disclosed lobbying spend has climbed meaningfully — from $4.0M in 2020 to $5.3M in 2024, a change of +31%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.
Eli Lilly and Company's disclosed lobbying covers 6 general issue areas — a moderate footprint. Filers in this range tend to engage on a coherent cluster of related topics rather than spreading effort across the federal agenda.
2 of 15 lobbyists reported by Eli Lilly and Company (13%) disclose prior federal government service — a small minority of the named bench.
Among the named bench, lobbyists with disclosed prior federal service include Kenneth L. Lewis (Former Senior Advisor, Office of the Vice President); Tony C. Podesta (Former Legislative Director, Senate HELP Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.
Within the Pharmaceutical & Health Products sector, Eli Lilly and Company ranks #8 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Eli Lilly and Company's $22.3M sits 33% above the sector average.
Eli Lilly and Company's LobbySpend Influence Score of 54/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.
Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.
Track Eli Lilly and Company's lobbying filings
Subscribe for LobbySpend updates by email. No spam, unsubscribe anytime.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2024 Oct-Dec | Mehlman Consulting | HCRCPT | 4 | $1.3M |
| 2024 Jul-Sep | Arnold & Porter | HCRMEDGOV+2 | 3 | $1.4M |
| 2024 Apr-Jun | Fierce Government Relations | HCRMEDPHA+1 | 2 | $1.3M |
| 2024 Jan-Mar | Van Scoyoc Associates | CPTPHAMED+2 | 1 | $1.4M |
| 2023 Oct-Dec | Holland & Knight | HCRCPTMED+1 | 4 | $1.1M |
| 2023 Jul-Sep | K&L Gates | PHAMEDTAX+1 | 1 | $1.2M |
| 2023 Apr-Jun | K&L Gates | PHAHCRMED+2 | 2 | $1.1M |
| 2023 Jan-Mar | Hogan Lovells | PHAMEDHCR+1 | 4 | $1.2M |
Eli Lilly and Company Lobbying FAQ
Eli Lilly and Company has spent $22.3M on federal lobbying across 6 policy areas. This includes spending on registered lobbyists and direct government contacts.
Eli Lilly and Company lobbies on 6 policy issues, including Health Issues, Pharmacy, Medical/Disease Research, Copyright/Patent/Trademark. These disclosures are filed quarterly with the Senate Office of Public Records.
Eli Lilly and Company has an Influence Score of 54/100 (Grade C). This proprietary score is based on total lobby spend (40%), policy issue breadth (30%), and revolving door connections (30%).
Eli Lilly and Company employs 15 registered lobbyists, of whom 2 have revolving door connections, meaning they previously held government positions before becoming lobbyists.
Eli Lilly and Company has contacted 7 government entities as part of their lobbying activities, including Dept of Labor, U.S. Senate, Dept of the Treasury.
Explore Other Lobbying Organizations
$387.8M lobbying spend · Trade Association · Influence Score B
$348.2M lobbying spend · Real Estate · Influence Score B
$135.8M lobbying spend · Pharmaceutical & Health Products · Influence Score B
$128.0M lobbying spend · Healthcare · Influence Score B
Lobbying data is sourced from quarterly Lobbying Disclosure Act (LDA) filings with the Senate Office of Public Records. Influence Scores combine total spend (40%), issue breadth (30%), and revolving door connections (30%). Filings may be amended after initial submission.